Legal status · United States
Is Tirzepatide with BPC-157 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Tirzepatide with BPC-157 is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 1 human study is cited on its profile.
Tirzepatide with BPC-157 in the United States at a glance
| Classification | Not approved; research use only |
|---|---|
| Note | Tirzepatide is FDA approved; BPC-157 is not approved and cannot lawfully be compounded, so any premixed product is unlawful on the second ingredient. |
| FDA approval status | Tirzepatide is approved. BPC-157 is not approved, was reviewed by FDA staff in July 2026 with no adequate human data found, and is not a permitted compounding ingredient. The combination has never been evaluated. |
| Human studies cited | 1 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Tirzepatide with BPC-157 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Tirzepatide with BPC-157 is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Tirzepatide with BPC-157 is
The same pairing logic as the semaglutide version with a larger weight loss effect on one side and the same empty file on the other. Tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks; BPC-157 has five human studies totalling under 110 subjects, none by the route used here. The combination has never been studied and BPC-157 cannot lawfully be compounded in the United States.
Tirzepatide's effect size makes the lean mass question sharper than it is with semaglutide. In SURMOUNT-1, 57% of the 15 mg group lost 20% or more of body weight over 72 weeks, against 3% on placebo.
Mechanism: Tirzepatide agonises both the GIP and GLP-1 receptors, reducing appetite and slowing gastric emptying. BPC-157 is described in rodent studies as promoting angiogenesis and modulating growth factor and inflammatory signalling.
Regulatory history: Tirzepatide is approved. BPC-157 is not approved, was reviewed by FDA staff in July 2026 with no adequate human data found, and is not a permitted compounding ingredient. The combination has never been evaluated.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Tirzepatide with BPC-157 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Tirzepatide with BPC-157 in other countries
Frequently asked questions
Is Tirzepatide with BPC-157 legal in the United States?
No. Tirzepatide with BPC-157 is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 1 human study is cited on its profile. Note: Tirzepatide is FDA approved; BPC-157 is not approved and cannot lawfully be compounded, so any premixed product is unlawful on the second ingredient.
Can I buy Tirzepatide with BPC-157 in the United States?
No approved product exists to buy. In the United States Tirzepatide with BPC-157 is classified as "Not approved; research use only", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Tirzepatide is FDA approved; BPC-157 is not approved and cannot lawfully be compounded, so any premixed product is unlawful on the second ingredient.
Is Tirzepatide with BPC-157 FDA approved?
No. FDA status: Tirzepatide is approved. BPC-157 is not approved, was reviewed by FDA staff in July 2026 with no adequate human data found, and is not a permitted compounding ingredient. The combination has never been evaluated.. Current US classification: "Not approved; research use only". On the evidence, 1 human study is cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Tirzepatide with BPC-157 live on its compound profile.
Tirzepatide with BPC-157 profileThis page is general information about the regulatory status of Tirzepatide with BPC-157 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.